anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses an ointment for treatment of psoriasis. The ointment is prepared from the following raw materials by weight: 8-15 parts of Nauclea officinalis, 15-20 parts of euphorbia, 8-12 parts of rhizoma zingiberis preparata, 20-25 parts of Zaocys dhumnades, 5-10 parts of natural indigo, 8-15 parts of medicated leaven, 20-28 parts of coix seed, and 80-150 parts of Vaseline. The drug provided by the invention can be used for treating psoriasis, can achieve low recurrence rate after use, has high efficacy, and reduce itching and pain of the skin. The Nauclea officinalis has the effects of clearing away heat and toxic materials, eliminating swelling and relieving pain, and can treat dermatitis-eczema, acute tonsillitis, pharyngolaryngitis, mastitis, enteritis, bacillary dysentery, urinary tract infection, cholecystitis, ulcer of lower limb, tinea pedis infection, furuncle and abscess. The Zaocys dhumnades has the effects of dispelling wind, dredging collaterals, and relieving spasm, and can treat rheumatism and obstinate arlhralgia, leprosy and mange, scrofula and malignant sores. By using a variety of drugs cooperatively, the therapeutic effect is improved.
BACKGROUND: Few clinical data are available on NEXN mutation carriers, and the gene's involvement in cardiomyopathies or sudden death has not been fully established. Our objectives were to assess the prevalence of putative pathogenic variants in NEXN and to describe the phenotype and prognosis of patients carrying the variants.
METHODS: DNA samples from consecutive patients with cardiomyopathy or sudden cardiac death/sudden infant death syndrome/idiopathic ventricular fibrillation were sequenced with a custom panel of genes. Index cases carrying at least one putative pathogenic variant in the NEXN gene were selected.
RESULTS: Of the 9516 index patients sequenced, 31 were carriers of a putative pathogenic variant in NEXN only, including 2 with double variants and 29 with a single variant. Of the 29 unrelated probands with a single variant (16 males; median age at diagnosis, 32.0 [26.0-49.0] years), 21 presented with dilated cardiomyopathy (prevalence, 0.33%), and 3 presented with hypertrophic cardiomyopathy (prevalence, 0.14%). Three patients had idiopathic ventricular fibrillation, and there were 2 cases of sudden infant death syndrome (prevalence, 0.46%). For patients with dilated cardiomyopathy, the median left ventricle ejection fraction was 37.5% (26.25-50.0) at diagnosis and improved with treatment in 13 (61.9%). Over a median follow-up period of 6.0 years, we recorded 3 severe arrhythmic events and 2 severe hemodynamic events.
CONCLUSIONS: Putative pathogenic NEXN variants were mainly associated with dilated cardiomyopathy; in these individuals, the prognosis appeared to be relatively good. However, severe and early onset phenotypes were also observed-especially in patients with double NEXN variants. We also detected NEXN variants in patients with hypertrophic cardiomyopathy and sudden infant death syndrome/idiopathic ventricular fibrillation, although a causal link could not be established.
PURPOSE:A forming bath agent, containing a carbonate and organic acid, and obtained by incorporating further silicon dioxide and/or calcium silicate therewith, capable of increasing the bath concentration of CO2 by foaming CO2 finer for a long period, and having high effect. CONSTITUTION:A foaming bath agent containing a carbonate, e.g. NaHCO3, Na2CO3 or sodium sesquicarbonate, and an organic acid, e.g. citric acid, tartaric acid, malic acid or succinic acid, and obtained by incorporating further silicon dioxide and/or calcium silicate in an amount of 0.1-20wt% based on the total composition therewith. Porous silica, obtained by dry or wet process or gelatinizing silica acid, and having 0.1-10mum average particle diameter is particularly preferably used as the silicon dioxide. Calcium silicate having 0.1-30mum average particle diameter in the form of a petal is preferred for the calcium silicate. The above-mentioned bath agent has improved effect on prevention of a chill after a bath, etc. and the performance is scarcely changed from that just after the production even on the storage for a long period.
This will be a single-site study to evaluate the effect of IV oxytocin on chronic pain in female adult patients with hypermobile EDS.

Oxytocin secretion in the body is dynamic and can be affected by multiple factors including the menstrual period. In order to have minimum variation between tested individuals we conduct this study in females at the same stage of their menstrual cycles. Hypermobile EDS is more prevalent in females and the symptoms are usually more severe in females and more females come to medical attention. We are not aware of any difference in the risk from using oxytocin in females vs males.

All participating individuals are affected with hypermobile-EDS (hEDS) with chronic moderate to severe pain. Study will include two periods of treatment - one with placebo and one with oxytocin and a one month period will be held in between the two treatments. Participants will be blinded to the order of treatment. Each period of treatment will start 7-10 days after the beginning of the menstrual cycle and will include 6 days of daily subjective pain evaluation using pain-evaluation questionnaire ('preinfusion evaluation') followed by three consecutive daily infusions (placebo or oxytocin). Response to treatment will be evaluated by questionnaire during 6 days after each three infusion days (placebo or oxytocin) . Additional questionnaires for evaluation of anxiety and depression will be used as well. Patients will be asked to wear ACTIHEART device (measures heart rate, heart rate variation, and activity levels) 3 days prior to infusion, during the 3 days of infusion, and in the 3 days after the last infusion day. For each infusion period, participants will arrive to the study site for three daily consecutive visits, each will last for 3-4 hours. Response variables will be collected prior, during and after each infusion. Patients will fill out pain evaluation questionnaires pre and post infusion and some questionnaires during the days of infusion. Blood pressure and heart rate measurements will be taken prior, during and after the infusion. Blood samples for measurements of oxytocin levels and blood samples for future analysis will be collected in some of the infusion days (before and after the infusion).
The involvement of γδ TCR-bearing lymphocytes in immunological memory has gained increasing interest due to their functional duality between adaptive and innate immunity. γδ T effector memory (TEM) and central memory (TCM) subsets have been identified, but their respective roles in memory responses are poorly understood. In the present study, we used subsequent mouse cytomegalovirus (MCMV) infections of αβ T cell deficient mice in order to analyze the memory potential of γδ T cells. As for CMV-specific αβ T cells, MCMV induced the accumulation of cytolytic, KLRG1+CX3CR1+ γδ TEM that principally localized in infected organ vasculature. Typifying T cell memory, γδ T cell expansion in organs and blood was higher after secondary viral challenge than after primary infection. Viral control upon MCMV reinfection was prevented when masking γδ T-cell receptor, and was associated with a preferential amplification of private and unfocused TCR δ chain repertoire composed of a combination of clonotypes expanded post-primary infection and, more unexpectedly, of novel expanded clonotypes. Finally, long-term-primed γδ TCM cells, but not γδ TEM cells, protected T cell-deficient hosts against MCMV-induced death upon adoptive transfer, probably through their ability to survive and to generate TEM in the recipient host. This better survival potential of TCM cells was confirmed by a detailed scRNASeq analysis of the two γδ T cell memory subsets which also revealed their similarity to classically adaptive αβ CD8 T cells. Overall, our study uncovered memory properties of long-lived TCM γδ T cells that confer protection in a chronic infection, highlighting the interest of this T cell subset in vaccination approaches.
BACKGROUND: Pediatric urolithiasis is relatively uncommon and is generally associated with predisposing anatomic or metabolic abnormalities. In the adult population, emergency department (ED) admissions have been associated with an increase in ambient temperature. The same association has not been evaluated in the pediatric population.
OBJECTIVES: To analyze trends in ED admissions due to renal colic in a pediatric population (≤ 18 years old) and to assess the possible effect of climate on ED admissions.
METHODS: We conducted a retrospective, multicenter cohort study, based on a computerized database of all ED visits due to renal colic in pediatric patients. The study cohort presented with urolithiasis on imaging during their ED admission. Exact climate data was acquired through the Israeli Meteorological Service (IMS).
RESULTS: Between January 2010 and December 2020, 609 patients, ≤ 18 years, were admitted to EDs in five medical centers with renal colic: 318 males (52%), 291 females (48%). The median age was 17 years (IQR 9-16). ED visits oscillated through the years, peaking in 2012 and 2018. A 6% downward trend in ED admissions was noted between 2010 and 2020. The number of ED admissions in the different seasons was 179 in autumn (30%), 134 in winter (22%), 152 in spring (25%), and 144 in summer (23%) (P = 0.8). Logistic regression multivariable analysis associated with ED visits did not find any correlation between climate parameters and ED admissions due to renal colic in the pediatric population.
CONCLUSIONS: ED admissions oscillated during the period investigated and had a downward trend. Unlike in the adult population, rates of renal colic ED admissions in the pediatric population were not affected by seasonal changes or rise in maximum ambient temperature.
Animal RNA viruses having a helical core and being viruses of the myxovirus e.g. Myxovirus influenzae-A, influenzae-B or paramyxovirus group e.g. Myxovirus parainfluenzae-3 or Simian virus-5 or the respiratory syncytial virus or rubella virus are purified or concentrated by precipitating the virus from an aqueous suspension thereof by adding to said suspension a water-soluble polyalkylene glycol and an electrolyte solution having a concentration of 0.15N in a neutral medium of pH 6.5 to 7.5 and separating the sediment containing the virus. The polyalkylene glycol may be polyethylene glycol of the formula H(OCH 2 CH 2 ) n OH where n is from 80 to 180 e.g. polyethylene glycol 6000, and the electrolyte is preferably NaCl. The precipitation is preferably carried out at pH 7.4 with a concentration of polyethylene glycol of 7.5% w/v. The suspension of the virus may be allowed to stand at 4 C for about an hour after the treatment with the polyalkylene glycol and is subsequently subjected to centrifugation at 2,000 to 10,000g for about 20 mins. or at 12,000g at a continuous flow rate of 50 to 100 ml per min. The sediment may be resuspended in a citric saline buffer optionally containing sucrose, phosphate-buffered saline solution or medium S.M. 199. Vaccines may be produced by inactivation of the virus.
1,267,825. Medical screening. SEARLE MEDIDATA Inc. 11 Sept., 1969 [12 Sept., 1968], No. 44835/69. Heading ASK. [Also in Division G4] In a medical screening system (see Division G4) a master station includes a computer and a scanner which addresses in a selected sequence each of a number of remote test stations which obtain selected medical data from a patient, each test station including a means for recognizing its unique address, a store for the medical data, means for encoding the data to a form suitable for the computer, and a device for transmitting the encoded data to the computer. The remote stations are arranged to transmit their own address if they have no data when called and the address is verified in the master station in order to detect malfunctions. Each remote station includes a punched card reader which accepts a card bearing the patient's identification number. The test stations may perform medical tests, e.g. hearing, vision, breathing, physique, electrocardiogram, and blood tests, the data from which is automatically processed by the computer.
The present invention is a method and technology system for improving brain health and cognitive ability using brain exercise to help dementia prevention, brain health, and cognitive improvement, which are essential for healthy longevity, in recognition of the fact that it is more important to live a healthy long life than to simply live a long life in the era of old age. The specific details of the invention consist of three brain exercise methods and technology systems centered on a step-by-step method and technology integration system for brain exercise. The first is a brain exercise method and technology system through nerve cells, which stimulate various nerve cells to stimulate brain nerve cells such that the stimulation of brain nerve cells helps to activate the brain and makes the brain healthy. As a practical task, brain exercise training methods utilizing neurons are executed, such as brain gymnastics, brain games, music activities, art activities, and positive energy activities. The second is a brain exercise method and technology system through memory, which is based on attention-focused memory activity, continuous memory activity, selective memory activity, and simultaneous memory activity, and in which audio-visual memory training is practiced through the principles of memory: input principle, storage principle, and withdrawal principle. The third is a brain exercise method and technology system through cognition, which is a method to help improve brain health and cognition by implementing various cognitive activities such as language, reading, music, recall, art, and brain cognitive activities which help cognition. The present invention aims to help prevent dementia, improve brain health and cognitive ability, and improve the health of seniors and the public.
Previous studies have reported a high occurrence of contrast-associated acute kidney injury (CA-AKI) in myocardial infarction (MI) patients undergoing primary percutaneous coronary intervention (PCI). However, the data on CA-AKI in MI patients who underwent elective PCI are limited. To evaluate the incidence of CA-AKI in MI patients undergoing elective PCI. The data were sourced from the Iodixanol-AKI Registry of MI patients scheduled to undergo elective PCI in 8 medical centers from May 2020 to November 2021. The participants were divided into three groups: acute, prior, and multiple MI. The outcomes measured were CA-AKI and the composite endpoint of major adverse renal and cardiovascular events (MARCE). The incidence of CA-AKI was 4.46% (37/830) in the MI patients, 4.40% (7/159) in the acute MI patients, 4.41% (22/499) in the prior MI patients, and 4.65% (8/172) in the multiple MI patients. Of note, 36 patients (97.30%) at AKI stage 1, and only 1 patient at AKI stage 2. There was no difference in the incidence of CA-AKI (P = 0.991) among the three groups. Multivariate regression analysis revealed that the independent risk factors for CA-AKI were diabetes and an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2. MARCE occurred in 3.4% (28/830) of the total patients and was not associated with either any subgroup of patients with MI or AKI. The incidence of CA-AKI was low and mainly limited to mildly impaired renal function in MI patients undergoing elective PCI.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of TEPEZZA was evaluated in two randomized, double-masked, placebo-controlled clinical studies (Study 1 [NCT:01868997] and Study 2 [NCT:03298867]) consisting of 170 patients with Thyroid Eye Disease (84 received TEPEZZA and 86 received placebo). Patients were treated with TEPEZZA (10 mg/kg for first infusion and 20 mg/kg for the remaining 7 infusions) or placebo given as an intravenous infusion every 3 weeks for a total of 8 infusions. The majority of patients completed 8 infusions (89% of TEPEZZA patients and 93% of placebo patients).

The most common adverse reactions (≥5%) that occurred at greater incidence in the TEPEZZA group than in the control group during the treatment period of Studies 1 and 2 are summarized in Table 1. In addition, menstrual disorders (amenorrhea, metrorrhagia, dysmenorrhea) were reported in approximately 23% (5 of 22 patients) of menstruating women treated with TEPEZZA compared to 4% (1 of 25 patients) treated with placebo in the clinical trials.
BACKGROUND: Acute myocardial infarction is still a leading cause of death worldwide, accounting for roughly three million deaths yearly. This study aimed to investigate the prevalence and factors associated with ST-Segment Elevation Myocardial Infarction and Non-ST Segment Elevation Myocardial Infarction in Iran.
METHODS: This cross-sectional study was conducted using the databases of the Fasa Registry on Acute Myocardial Infarction (FaRMI) and the Fasa Adult Cohort Study (FACS). chi-squared and one-way ANOVA tests were utilized to calculate the unadjusted associations between the study variables. A multivariate multinomial logistic regression model was also employed to determine the adjusted association of each independent variable with the risk of ST-elevation myocardial infarction (STEMI).
RESULTS: The prevalence of STEMI and non-STEMI was 31.60% and 11.80%, respectively. Multinomial logistic regression showed that older age, anemia, high WBC, and high creatinine levels were associated with higher odds of STEMI and non-STEMI compared to healthy individuals. In addition, based on the analysis being a woman(OR = 0.63,95%CI:0.51-0.78), anemia(OR = 0.67,95%CI:0.54-0.63)and hypertension (OR = 0.80,95%CI:0.65-0.97)decreased the likelihood of STEMI occurrence compared to non-STEMI, while high WBC(OR = 1.19,95%CI:1.15-1.23)increased the odds.
CONCLUSION: In this study, significant predictors of MI risk included age, gender, anemia, lipid profile, inflammation, and renal function. Subsequent investigations ought to prioritize the comprehensive understanding of the underlying mechanisms that drive these connections and assess the effectiveness of specific interventions aimed at diminishing the occurrence of MI and improving patient outcomes.
Subjects in this crossover arm will be assigned to 6 weeks on THC oral solution, then 6 weeks on THC/CBD oral solution, then 6 weeks on Placebo oral solution. Frequency of drug administration is 3-4 times a day.
Intravascular papillary endothelial hyperplasia, or Masson's tumour, is a benign lesion of the subcutaneous tissue and skin, characterised by a reactive proliferation of endothelial cells within a vessel. Although this pathology can occur at various sites, it is generally rare. Differential diagnosis with other benign lesions or malignancies can be challenging, and since its circumscribed nature is impossible to recognise with a biopsy, excision is frequently required.We present the case of a female patient with a history of bilateral breast cancer, treated with surgery, chemotherapy and radiotherapy, who developed a slowly growing, large bulging mass in the right axilla. Biopsies were benign, and the positron emission tomography-CT showed no hypermetabolism of the mass. However, due to the debilitating bleeding from the fragile mass and uncertainty about its biological behaviour, excision was performed. Pathological examination revealed an intravascular lesion with a central thrombus, characteristic of intravascular papillary endothelial hyperplasia.
PROBLEM TO BE SOLVED: To provide goumi candies containing tannin-containing food product of which the surfaces do not dissolve, and not become wet or tacky. SOLUTION: This candy composition of goumi (fruits of a tree, Elaeagnus multiflora) contains 0.2-1.0 wt.% of pectin on the solid basis. The tannin- containing food product means tea leaves or tea leaf extract. In one embodiment, the goumi candies is produced, for example, by adding powdery sugar to liquid sugar, and concentrating the mixture with heat to the BX sugar content of about 80. Then, tea leaves or tea extract, juice and flavors are formulated to the sugar concentrate in desired amounts and dissolved. Separately, a gelatin solution is prepared by dissolving gelatin in hot water. In addition, pectin solution is prepared by dissolving it in hot water.  The pectin solution, gelatin solution are added to the sugar liquid in order, they are concentrated by boiling down until the BX sugar content attains 78-80, cast into a mold made of corn starch and solidified in a cool and dark place.
Obesity is an ongoing pandemic and is associated with the development of heart failure (HF), and especially HF with preserved ejection fraction. The definition of obesity is currently based on anthropometric measurements but neglects the location and molecular properties of excess fat. Important depots associated with HF development are subcutaneous adipose tissue and visceral adipose tissue, both located in the abdominal region, and epicardial adipose tissue (EAT) surrounding the myocardium. However, mechanisms linking these different adipose tissue depots to HF development are incompletely understood. EAT in particular is of great interest because of its close proximity to the heart. In this review, we therefore focus on the characteristics of different adipose tissue depots and their response to obesity. In addition, we evaluate how different mechanisms associated with EAT expansion potentially contribute to HF and in particular HF with preserved ejection fraction development.
HB-adMSCs are autologous, adipose-derived mesenchymal stem cells. Four intravenous infusions will be administered on weeks 0, 2, 6, and 8 at a dose of 2 x 10\^8 total HB-adMSC cells.
The immune system is involved in hypertension development with different immune cells reported to have either pro or anti-hypertensive effects. In hypertension, immune cells have been thought to infiltrate blood pressure-regulating organs, resulting in either elevation or reduction of blood pressure. There is controversy over whether macrophages play a detrimental or beneficial role in the development of hypertension, and the few existing studies have yielded conflicting results. This study aimed to determine the effects of angiotensin II (Ang II) salt-induced hypertension on renal immune cells and to determine whether renal macrophages are involved in the induction of hypertension. Hypertension was induced by administration of Ang II and saline for two weeks. The effects of hypertension on kidney immune cells were assessed using flow cytometry. Macrophage infiltration in the kidney was assessed by immunohistochemistry and kidney fibrosis was assessed using trichrome stain and kidney real time-qPCR. Liposome encapsulated clodronate was used to deplete macrophages in C57BL/6J mice and investigate the direct role of macrophages in hypertension induction. Ang II saline mice group developed hypertension, had increased renal macrophages, and had increased expression of Acta2 and Col1a1 and kidney fibrotic areas. Macrophage depletion blunted hypertension development and reduced the expression of Acta2 and Col1a1 in the kidney and kidney fibrotic areas in Ang II saline group. The results of this study demonstrate that macrophages infiltrate the kidneys and increase kidney fibrosis in Ang II salt-induced hypertension, and depletion of macrophages suppresses the development of hypertension and decreases kidney fibrosis. This indicates that macrophages play a direct role in hypertension development. Hence macrophages have a potential to be considered as therapeutic target in hypertension management.